Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results beating Wall Street’s revenue expectations , but sales fell by 4.3% year on year to $37.15 million. Its ...

PacBio reported $36.9 million in Q1 revenue, beating consensus, with record consumable sales and steady Revio system pull-through. Company to cut $45–$50 million in annualized costs by year-end ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants.

PacBio (PACB) and Intus Bio unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform and PacBio’s HiFi sequencing technology. By ...

UBS downgraded PacBio (PACB) to Neutral from Buy with a $2 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today ...

(MENAFN- GlobeNewsWire - Nasdaq) MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Revenue of ...

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its slew of strategic deals over the past few months. The optimism, led by a solid fourth-quarter ...

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium. This global consortium brings together ...

Executive previously served as chief financial officer of Moderna, Amgen, and 3M. PacBio, a developer of sequencing solutions, announced the appointment of David Meline to its board of directors.

Please use one of the following formats to cite this article in your essay, paper or report: APA PacBio. (2023, October 11). PacBio Announces Complete Computational Workflow for Human Whole Genome ...